skip to Main Content

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer’s Disease


Brief Summary:

The name of this trial is MissionAD2. This phase 3 study consists of a Core and Open Label
Extension (OLE) Phase in participants with Early Alzheimer’s Disease (EAD), and will be
conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment,
multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month
treatment, one group study. The data for end points for the studies E2609-G000-301
(NCT02956486) and E2609-G000-302 (NCT03036280) will be pooled for a combined total of 1900


Inclusion Criteria:

Core Study

– Mild cognitive impairment due to AD or mild AD dementia including

1. MMSE score equal to or greater than 24

2. CDR global score of 0.5

3. CDR Memory Box score of 0.5 or greater

– Impaired episodic memory confirmed by a list learning task

– Positive biomarker for brain amyloid pathology as indicated by either amyloid PET or
CSF AD assessment or both

Extension Phase

•Participants who complete the Core Study

Exclusion Criteria:

Core Study

– Females who are breastfeeding or pregnant at Screening or Baseline. Females of
child-bearing potential must use a highly effective method of contraception throughout
the entire study period and for 28 days after study drug discontinuation

– Any condition that may be contributing to cognitive impairment above and beyond that
caused by the participant’s AD

– Participants with a history of seizures within 5 years of Screening

– History of transient ischemic attacks or stroke within 12 months of Screening

– Psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, delusions,

– Suicidal ideation or any suicidal behavior within 6 months before Screening or has
been hospitalized or treated for suicidal behavior in the past 5 years

– Have any contraindications to MRI scanning or

1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI

2. Exhibit other significant pathological findings on brain MRI.

– Participants who have a history of moderate to severe hepatic impairment (eg,
Child-Pugh Class B or C)

– Results of laboratory tests conducted during Screening that are outside the following

1. Absolute lymphocyte count below the lower limit of normal (LLN)

2. Thyroid stimulating hormone above normal range

3. Abnormally low Vitamin B12 levels

– Participants at increased risk of infection

– Have received any live vaccine/live attenuated vaccine in the 3 months before

– Any chronic inflammatory disease that is not adequately controlled or that requires
systemic immunosuppressive or immunomodulatory therapy

– Any other clinically significant abnormalities

– Severe visual or hearing impairment

– A prolonged corrected QT (QTc) interval (QTcF greater than 450 milliseconds [ms])

– Malignant neoplasms within 5 years of Screening

– Known or suspected history of drug or alcohol abuse

– Taking prohibited medications, which must be reviewed with the Investigator

– Have participated in a recent clinical study

Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.


  • Facility #1, Bellflower, California, United States, 90706
  • Facility #1, Glendale, California, United States, 91204
  • Facility #1, Irvine, California, United States, 92614
  • Facility #1, Laguna Hills, California, United States, 92653
  • Facility #1, Lomita, California, United States, 90717
  • Facility #1, Los Angeles, California, United States, 90095
  • Facility #1, Oceanside, California, United States, 92056
  • Facility #1, Palo Alto, California, United States, 94304
  • Facility #1, Riverside, California, United States, 92506
  • Facility #2, Santa Ana, California, United States, 92704
  • Facility #1, Santa Ana, California, United States, 92705
  • Facility #1, Santa Monica, California, United States, 90404
Back To Top